Search Results
Your search for ,Any matches 8114 pages
Showing 1301 - 1350Intensive Remission Induction Chemotherapy vs Less Intensive Approach Prior to Transplant for Relapsed/Refractory AML
Intensive salvage therapy with the goal of achieving complete remission prior to allogeneic hematopoietic cell transplantation (alloHCT) may not be necessary in some patients with relapsed or refractory acute myeloid leukemia (AML), according to the results of the phase III ASAP trial presented at...
The Influence of Structural Racism and Poverty on Outcomes in Leukemia
In the United States, Black American patients with acute myeloid leukemia (AML) have notably worse survival outcomes compared to White patients. In addition, Black patients are less likely to receive intensive chemotherapy and undergo allogeneic stem cell transplants. Many researchers have reported ...
Northwell Receives Gift From Trustee Roy J. Zuckerberg to Create First Cancer Hospital and Cancer Campus on Long Island
Northwell Health recently announced a gift from longtime trustee Roy J. Zuckerberg to create the R.J. Zuckerberg Cancer Hospital at Long Island Jewish (LIJ) Medical Center—Long Island’s first cancer hospital—and to establish the R.J. Zuckerberg Cancer Center, Northwell’s largest ambulatory cancer...
Being on the Other Side: An Oncologist’s Perspective on Grieving
As an oncologist, I had cared for patients facing grave illness and death. I imagined the loss of loved ones and expected grief to be an unbearable sadness, most poignant in the earliest days and lessening with time. I somehow expected that counseling people who grieved would make me more prepared. ...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
First Adenoviral Vector–Based Gene Therapy for High-Risk BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
On December 16, 2022, nadofaragene firadenovec-vncg, an adenoviral vector–based gene therapy, was approved for patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.1 Supporting Efficacy Data...
Risks of Cardiovascular and Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy
In a single academic hospital network retrospective case-control study reported in JACC:CardioOncology, Charlotte Lee, MD, of Columbia University Irving Medical Center, New York, along with senior author Tomas Neilan, MD, MPH, of Massachusetts General Hospital and colleagues found that patients...
Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but...
FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Julie A. Schneider, PhD, Associate Director for Research Strategy and Partnerships, OCE; Jennifer J. Gao, MD,...
Interventions to Improve Skin Cancer Surveillance in Childhood Cancer Survivors Who Received Radiotherapy
In a study (Advancing Survivors Knowledge; ASK) reported in the Journal of Clinical Oncology, Geller et al found that three patient- and patient/physician-based interventions to improve skin cancer surveillance among childhood cancer survivors treated with radiotherapy resulted in increased rates...
NAPOLI-3: First-Line NALIRIFOX Regimen Improves Overall Survival in Metastatic Pancreatic Cancer
In the phase III NAPOLI-3 trial in previously untreated patients with metastatic pancreatic cancer, the NALIRIFOX regimen significantly improved overall survival and progression-free survival over nab-paclitaxel plus gemcitabine. NALIRIFOX contains liposomal irinotecan, fluorouracil, leucovorin,...
Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation
On December 1, 2022, the IDH1 inhibitor olutasidenib was approved for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1 The FDA simultaneously approved the Abbott...
Futibatinib in Previously Treated Patients With Advanced FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
In a phase II study (FOENIX-CCA2) published in The New England Journal of Medicine, Lipika Goyal, MD, and colleagues found that the next-generation, covalently binding FGFR1-4 inhibitor futibatinib showed activity in previously treated patients with unresectable or metastatic FGFR2-altered...
CLL2-GIVe Trial: Regimen of Obinutuzumab, Ibrutinib, and Venetoclax Effective in High-Risk CLL
The first-line combination of obinutuzumab, ibrutinib, and venetoclax appears to be effective in treating high-risk chronic lymphocytic leukemia (CLL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.1 Results of the CLL2-GIVe trial, which...
Tremelimumab-actl in Combination With Durvalumab for Unresectable Hepatocellular Carcinoma
On October 21, 2022, tremelimu-mab-actl was approved by the U.S. Food and Drug Administration (FDA) for use in combination with durvalumab in the treatment of unresectable hepatocellular carcinoma.1 Supporting Efficacy Data Approval was based on a comparison of overall survival in the...
Expert Point of View: Neil J. Shah, MBBS
Neil J. Shah, MBBS, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, called the cohort study “one of a kind” because of the ability to match baseline cohorts of people living with and without HIV and metastatic non–small cell lung cancer. “These findings should be very...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
Ensuring a More Diverse, Equitable, and Inclusive Workforce Within the SWOG Cancer Research Network
For more than 2 decades, Don S. Dizon, MD, FACP, FASCO, has devoted his medical career to the care of women’s cancers and the sexual health of cancer survivors of all genders and sexual identities. Early in his career, Dr. Dizon founded the Center for Sexuality, Intimacy, and Fertility at Women...
Appendectomy With or Without Hemicolectomy for 1- to 2-cm Appendiceal Neuroendocrine Tumors
In a European retrospective cohort study reported in The Lancet Oncology, Nesti et al found evidence that right-sided hemicolectomy is not indicated in patients who had complete resection, via appendectomy, of appendiceal neuroendocrine tumors (NETs) measuring 1 to 2 cm. As stated by the...
Neoadjuvant Gemcitabine/Cisplatin in High-Risk Upper Tract Urothelial Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Coleman et al found that neoadjuvant split-dose gemcitabine and cisplatin produced a high rate of pathologic response in patients with high-risk localized upper tract urothelial carcinoma. The investigators also showed that...
Study Suggests Ibrutinib May Obviate Need for Autologous Stem Cell Transplantation in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
Study Suggests Ibrutinib May Obviate Need for ASCT in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide in Maintenance Therapy After ASCT in Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Dominik Dytfeld, MD, PhD, and colleagues, an unplanned interim analysis of the phase III ATLAS trial has shown improved progression-free survival with carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide alone as maintenance after autologous stem...
American Cancer Society’s Cancer Statistics 2023 Report Released
The American Cancer Society has released its Cancer Statistics 2023 report, which showed that overall cancer mortality has dropped by 33% since 1991, averting an estimated 3.8 million cancer deaths. Data in the report, which was published by Siegel et al in CA: A Cancer Journal for Clinicians, also ...
Circulating Tumor DNA Profiling and Outcomes in CNS Lymphoma
In a German study reported in the Journal of Clinical Oncology, Mutter et al found that circulating tumor DNA (ctDNA) identified prior to and during treatment was associated with poorer outcomes in patients with central nervous system (CNS) lymphoma. Study Details The study included 92 patients...
Subcutaneous Epcoritamab for Relapsed or Refractory Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Catherine Thieblemont, MD, PhD, and colleagues, findings in a dose-expansion cohort of the phase I/II EPCORE NHL-1 study indicated high activity of the subcutaneous CD3 x CD20 T-cell–engaging bispecific antibody epcoritamab in patients with...
Experts Publish Consensus Statement on Classification System for Pathology and Diagnosis of Melanocytic Lesions
In recognition of continuing issues with the process of melanocytic pathology assessments, an expert panel of three dermatopathologists—with assistance from an expert team of researchers—has developed and now revised the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis schema...
Neoadjuvant Immunotherapy in Patients With Localized dMMR Colorectal Cancer
Investigators discovered that PD-1 inhibition prior to surgery may be effective for patients with localized mismatch repair–deficient or microsatellite instability–high (dMMR/MSI-H) colorectal cancer, according to a study published by Xiao et al in JNCCN–Journal of the National Comprehensive Cancer ...
New Scoring System Measures Inflammation Levels, May Improve Risk Stratification in AML
Researchers have discovered that severe inflammation may weaken the body’s ability to kill cancerous blood cells in patients with acute myeloid leukemia (AML), according to a new study published by Lasry et al in Nature Cancer. With bone marrow samples from 20 adults and 22 children with AML, the...
Older Minority Patients With Cancer Face Inequities in Opioid Access Near the End of Life
Research shows that pain is a common byproduct of cancer and its treatment, with approximately 55% of patients undergoing active treatment experiencing pain, and more than 66% of patients with advanced disease experiencing pain. According to the ASCO guideline on the use of opioids for adults with...
Study Identifies Potential Molecular Differences Between Primary Breast Cancer and Its Metastases
Researchers have identified unique molecular features responsible for the development and progression of metastatic breast cancer, according to a novel study published by Garcia-Recio et al in Nature Cancer. They discovered that one of the key features involves changes in the immune system that are ...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
In the phase I/II CodeBreaK 100 trial reported in The New England Journal of Medicine, John H. Strickler, MD, and colleagues found that the KRAS G12C inhibitor sotorasib showed activity in previously treated patients with advanced pancreatic cancer and a KRAS G12C mutation. Study Details In the...
Effect of Adjuvant Chemotherapy on Survival in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy
In a retrospective matched-cohort study reported in JAMA Oncology, Sugawara et al found that receipt of adjuvant chemotherapy improved survival vs no adjuvant chemotherapy in patients with pancreatic adenocarcinoma who received curative-intent surgery following multiagent neoadjuvant chemotherapy....
Adagrasib With or Without Cetuximab in Previously Treated Patients With Metastatic Colorectal Cancer and a KRAS G12C Mutation
In the phase I/II KRYSTAL-1 trial reported in The New England Journal of Medicine, Rona Yaeger, MD, and colleagues found that the KRAS G12C inhibitor adagrasib showed activity alone and in combination with cetuximab in heavily pretreated patients with metastatic colorectal cancer and mutated KRAS...
Prostate Cancer Screening Among Primary Care Providers
Investigators recently examined prostate cancer screening among primary care providers and found that screening tests were frequently used—even when they provide little value to patients, according to a new study published by Gillette et al in the Journal of the American Board of Family Medicine....
KEYNOTE-394: Pembrolizumab as Second-Line Therapy in Asian Patients With Advanced HCC
As reported in the Journal of Clinical Oncology by Qin et al, the phase III KEYNOTE-394 trial showed overall and progression-free survival benefits with pembrolizumab vs placebo in previously treated Asian patients with advanced hepatocellular carcinoma (HCC). Study Details The double-blind trial...
Study Compares the Cost and Efficacy of Anticoagulant Therapies
Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati showed that direct oral anticoagulants (DOACs) are more effective—and more cost-effective—than low–molecular-weight heparin for treating cancer-associated thrombosis. A study published by Gulati et al in...
Risk of Incident Lung Cancer in Individuals With Clonal Hematopoiesis
In a study reported in the Journal of Clinical Oncology, Tian et al found that clonal hematopoiesis was associated with an increased risk of subsequent lung cancer, independent of known risk factors. Study Details Two nested case-control studies were performed. One included 832 incident lung cancer ...
Hypofractionated 3-Week Course of Preoperative Radiotherapy for Soft-Tissue Sarcomas
In a single-center phase II trial (HYPORT-STS) reported in The Lancet Oncology, Guadagnolo et al found that a hypofractionated 3-week course of preoperative radiotherapy was safe in patients with soft-tissue sarcomas and may serve as an alternative to conventionally fractionated radiotherapy in...
Updated Position Statement on Drug Repository Programs Aims to Increase Access to Treatment
ASCO recently released an updated position statement on drug repository programs. The update shifts ASCO’s position to allow donation of oral cancer drug treatments in an open distribution system—which are drugs that have left the supply chain and have been dispensed to patients. ASCO’s previous...
Preexisting Autoimmune Disease and Risk for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy for Cancer
In a single academic hospital network retrospective case-control study reported in JACC: CardioOncology, Lee et al found that patients with vs without preexisting autoimmune disease who received immune checkpoint inhibitor therapy for cancer had significantly increased risk of cardiovascular...
Mirvetuximab Soravtansine for FRɑ-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted mirvetuximab soravtansine-gynx accelerated approval for patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three...
Concomitant and Sequential Nivolumab, Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Bröckelmann et al, final results of the German Hodgkin Study Group phase II NIVAHL trial indicate nearly 100% progression-free survival and 100% overall survival at 3 years among patients with early-stage unfavorable classical Hodgkin lymphoma...
A Lifelong Love of Science Leads to a Leadership Role in Oncology for Laurie Glimcher, MD
For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal...
How ASCO and the Oncology Community Came Together to Discuss Progress in Global Cancer Control and the Challenges Ahead
After a 4-year in-person hiatus because of the COVID-19 global pandemic, the World Cancer Congress, hosted by the Union for International Cancer Control (UICC), held its first hybrid in-person and virtual meeting in October in Geneva. The conference brought together more than 2,000 attendees from...
From the Clinic to the Lab: Overcoming Resistance to Immune Checkpoint Therapy
As a result of breakthroughs in immune checkpoint inhibitors over the past decade, immunotherapy has joined surgery, radiation therapy, and chemotherapy as one of the pillars of cancer treatment. However, nearly half of patients still do not benefit from immune checkpoint blockade. During the 2022...
Study Finds Lifileucel Active in Advanced Melanoma After Disease Progression on Immune Checkpoint Inhibitors
Cell therapy with tumor-infiltrating lymphocytes (TIL) may address an important unmet need for patients with difficult-to-treat melanoma after disease progression on immune checkpoint inhibitors, according to data presented during the 2022 Society for Immunotherapy of Cancer (SITC) Annual ...
Research Exposes Inequities in Health-Care Access and Delivery for Blood Disorders
Several studies presented during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition uncovered significant disparities in medical care and health outcomes among patients of different racial backgrounds, nationalities, and socioeconomic status across a range of blood...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
FDA Approves FoundationOne Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors
On December 21, Foundation Medicine, Inc, announced that the U.S. Food and Drug Administration (FDA) approved its FoundationOne Liquid CDx as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions...
